Home  |  About JAPTR |  Editorial board  |  Search |  Ahead of print  |  Current issue  |  Archives |  Submit article  |  Instructions  |  Subscribe  |  Advertise  |  Contacts  |Login 
Users Online: 167   Home Print this page Email this page Small font sizeDefault font sizeIncrease font size

 Table of Contents  
Year : 2010  |  Volume : 1  |  Issue : 4  |  Page : 401-405  

Synthesis and antimalarial evaluation of some 4-quinazolinone derivatives based on febrifugine

1 Bengal Institute of Pharmaceutical Sciences, Kalyani, Nadia, West Bengal, India
2 IT consultant, Schrödinger LCC, Moradabad, Uttar Pradesh - 244001, India
3 Pharmacy College, IFTM, Lodhipur Rajput, Moradabad, Uttar Pradesh - 244001, India
4 Division of Pharmacology, Department of Pharmaceutical Technology, Jadavpur University, Kolkata, West Bengal, India

Date of Web Publication3-Feb-2011

Correspondence Address:
Debanjan Sen
Bengal institute of Pharmaceutical Sciences SPLPM campus, Kalyani, Nadia, West Bengal
Login to access the Email id

Source of Support: Bengal Institute of Pharmaceutical Sciences, Kalyani and Jadavpur University, Kolkata, Conflict of Interest: None

DOI: 10.4103/0110-5558.76439

Rights and Permissions

A series of 2-substituted and 2,3-substituted quinazolin -4(3H)-one derivatives were designed and synthesized based on the structure of febrifugine. The structures of the new compounds were confirmed by spectral analysis. The in vivo biological activity test results indicated that those compounds exhibited antimalarial activities against Plasmodium berghei in mice, at a dose of 5 mg/kg. Compared to Chloroquine and Artemisinin, these compounds have the advantages of shorter synthetic routes and consequently are highly cost effective in nature.

Keywords: Antimalarial activity, febrifugine, Plasmodium berghei, 4-quinazolinone

How to cite this article:
Sen D, Banerjee A, Ghosh AK, Chatterjee TK. Synthesis and antimalarial evaluation of some 4-quinazolinone derivatives based on febrifugine. J Adv Pharm Technol Res 2010;1:401-5

How to cite this URL:
Sen D, Banerjee A, Ghosh AK, Chatterjee TK. Synthesis and antimalarial evaluation of some 4-quinazolinone derivatives based on febrifugine. J Adv Pharm Technol Res [serial online] 2010 [cited 2023 Feb 2];1:401-5. Available from: https://www.japtr.org/text.asp?2010/1/4/401/76439

   Introduction Top

Malaria is a life-threatening disease even in this decade. Studies have shown that every year throughout the world more than 300 million people suffer from malaria infections and millions of people including children die due to this disease. [1],[2],[3] Due to the ongoing development of resistance of Plasmodium falciparum to conventional antimalarial drugs, malaria has become a major global problem and efforts to discover new agents against multi-drug resistant Plasmodium strains are long-term and essential tasks for researchers. [4] Medicinal agents based on novel mechanisms of action are, therefore, required to overcome the increasing resistance and to control an ever increasing number of epidemics caused by the malaria parasite. [5]

In order to find new and effective antimalarial drugs with a simpler structure and with a low cost synthetic methodology, few 2,3-substituted quinazolin-4(3H)-one derivatives were designed and synthesized according to the structural features of febrifugine [[Figure 1]a] which is obtained from Chinese plant roots of Dichroa febrifuga Lour. (Chinese name: Cha΄ng Shan), a saxifragaceous plant that has been employed against malaria fevers, and no parasite resistant to D. febrifuga has been reported. Two alkaloids, i) febrifugine and ii) isofebrifugine [[Figure 1]b], were isolated from D. febrifuga as active principles against malaria. [6]
Figure 1 :(a) Febrifugine and (b) Iso-febrifugine

Click here to view

Due to numerous toxic effects, Febrifugine is not a successful drug candidate. [7] The synthetic derivative of febrifugine, 3"-ketofebrifugine [Figure 2] (Kikuchi et al. 2002), is cited as a good candidate for clinical trials (EC 50 =2.0Χ10 8 ). To assess the biological properties of these alkaloids in detail, studies were carried out on the antimalarial properties of some chemical entities based on febrifugine. A lot of work on the antimalarial activity of many febrifugine analogues has been reported previously. [8],[9],[10],[11]
Figure 2 :Ketofebrifugine

Click here to view

But in all cases, their synthetic methodologies are either costlier or the compounds do not possess promising antimalarial activity. It has been demonstrated that most febrifugine analogues bearing a modified or non-modified 4-quinazolinone moiety are active, [12] from this line of evidence; it can easily be assumed that the 4-quinazolinone moiety of natural febrifugine possesses activity against the malaria parasite. The 3-hydroxy piperidin-2-yl-propane-2-one at N3 position of the 4-quinazolinone ring was identified as an important fragment for producing biological activity. These results suggest that the 4-quinazolinone moiety, the nitrogen atom of the piperidine ring and propyl chain are necessary for the antimalarial activity. In the present work, some 2-substituted quinazolinones with 1-(2-hydroxy propyl) pyrolidine-2-carboxylic acid substitution at N3 position of quinazolinone ring were synthesized and the antimalarial property of those compounds was investigated using in vivo screening method.

   Materials and Methods Top

Melting point was determined using a Sturat SMP heating stage microscope and was uncorrected. Nuclear magnetic resonance (NMR) 1 H spectra were recorded on a Bruker AV300 Supercon NMR System with chemical shifts being represented in parts per million (ppm) and with tetramethylsilane (TMS) as an internal standard. Electron impact Mass spectra (EI-MS), High resolution Mass spectra (HRMS) and Fast atom bombardment mass spectroscopy(FAB MS) were recorded on an Autospec-Ultima ETOF MS spectrometer at an ionization voltage of 70 eV. Reactions were monitored by thin layer chromatography (TLC) and the spots were visualized by spraying the TLC plates with 2% ninhydrin/acetic acid w/v solution. The TLC employed pre-coated silica gel plates (aluminum sheets 20Χ20 cm, silica gel 60 F254 of Merck K GaA). All solvents and reagents used were of analytical grade and obtained from Merck, India. All solvents used were of spectral grade or distilled prior to use.

As shown in [Figure 3], the important intermediate 4 was synthesized by the reaction of commercially available 4-piperidone (3) with epibromohydrin in an anhydrous condition. Compounds 5a-h were prepared using simple coupling reaction of 4 with various quinazolinones using NaH in dry (Di methyl formamide) DMF.
Figure 3 :Reagent and condition: i) Edpibromohydrine;K2CO3, Acetone, ii) Quinazolinone; NaH, DMF R=a) H, b) Me, c) Ph, d) pCl-Ph, e) pMe-Ph, f) pBr-Ph, g) pF-Ph, h) 2-Br-Ph

Click here to view

1-(oxiran-2-ylmethyl) piperidin-4-one (4)

To an ice-cold solution of 4-piperidone (0.5 g) in dry acetone and K 2 CO 3 (0.53 g, 1.2 eq), epibromohydrin (0.68 ml) was added dropwise in nitrogen atmosphere. It was stirred overnight at room temperature. Then, the reaction mixture was filtered off. After evaporation of the solvent under vacuum, it was directly loaded into a column of silica gel and eluted with 0.2-1% EtOAc/hexane. Compound 4 was isolated as a colorless liquid.

1 H NMR (300 MHz, CDCl 3) δ 3.30-3.28 (m, 1H), 3.01 (t, J = 5.7 Hz, 2H), 2.84-2.72 (m, 3H), 2.66-2.51 (m, 6H), 2.31 (dd, J = 12.4, 4.9 Hz, 1H).

2,3-substituted quinazolin-4(3H)-one derivative general method of preparation

To an ice-cooled suspended solution of sodium hydride (1.5 eq) in dry DMF, various quinazolin-4(3H)-ones [13] was added. The reaction mixture was then stirred at 0°C for 30 min. This was followed by dropwise addition of corresponding oxiranes (1.2 eq) in dry DMF. The mixture was then refluxed at 75-80°C for 5 hours and was stirred overnight at room temperature. [9] Then, the reaction mixture was quenched with 30% HCl solution and extracted with DCM, dried over brine and anhydrous sodium sulfate and evaporated by distillation. The crude mixture was purified by column chromatography over silica gel.

Typical synthesis of 3-(2-hydroxy-3-(4-oxopiperidin-1-yl) propyl) quinazolin-4(3H)-one (5a)

To an ice-cooled suspended solution of sodium dydride (0.266 g) in dry DMF (5 ml), quinazolin-4(3H)-one (0.2 g) was added. The reaction mixture was then stirred at 0°C for 30 min. Then, ethyl 1-(oxiran-2-ylmethyl) pyrrolidine-2-carboxylate (0.326 g) in dry DMF was added dropwise. The mixture was then refluxed at 75-80°C for 5 hours and was stirred overnight at room temperature. Then, the reaction mixture was quenched with 30% HCl solution (1.3 ml) and extracted with DCM (10Χ3 ml), dried over brine and anhydrous sodium sulfate and evaporated by distillation. The crude mixture was purified by column chromatography over silica gel (2% MeOH/CHCl 3 ) to furnish 3-(2-hydroxy-3-(4-oxopiperidin-1-yl) propyl) quinazolin-4(3H)-one. After re-crystallization with DMF, a white crystalline solid was obtained with MP 207°C.

1H NMR (300 MHz, DMSO) δ 7.96 (s, 1H), 7.72 (d, J = 24.4 Hz, 2H), 7.43 (d, J = 15.4 Hz, 2H), 4.04 (s, 1H), 3.70 (s, 1H), 3.56 (s, 1H), 3.24-3.10 (m, 3H), 3.04 (s, 1H), 2.67-2.47 (m, 7H).

3-(2-hydroxy-3-(4-oxopiperidin-1-yl) propyl)-2-methylquinazolin-4(3H)-one (5b)

1H NMR (300 MHz, DMSO) δ 7.93 (s, 1H), 7.67 (s, 1H), 7.39 (d, J = 18.8 Hz, 2H), 6.30 (s, 1H), 4.51 (s, 1H), 3.72 (s, 1H), 3.25-3.03 (m, 3H), 2.70-2.44 (m, 10H), 2.29 (s, 1H).

3-(2-hydroxy-3-(4-oxopiperidin-1-yl) propyl)-2-phenylquinazolin-4(3H)-one (5c)

1H NMR (300 MHz, DMSO) δ 7.98 (s, 1H), 7.78-7.25 (m, 8H), 6.17 (s, 1H), 3.88 (d, J = 32.9 Hz, 2H), 3.30-3.21 (m, 2H), 3.17-2.90 (m, 3H), 2.76-2.69 (m, 2H), 2.64-2.46 (m, 4H).

2-(4-chlorophenyl)-3-(2-hydroxy-3-(4-oxopiperidin-1-yl) propyl) quinazolin-4(3H)-one (5d)

1H NMR (300 MHz, DMSO) δ 7.98 (s, 1H), 7.70 (s, 1H), 7.59-7.38 (m, 4H), 7.39-7.28 (m, 2H), 6.16 (s, 1H), 3.93 (s, 1H), 3.79 (s, 1H), 3.28-3.19 (m, 2H), 3.15-2.90 (m, 3H), 2.78-2.68 (m, 2H), 2.62-2.42 (m, 4H).

3-(2-hydroxy-3-(4-oxopiperidin-1-yl) propyl)-2-p-tolylquinazolin-4(3H)-one (5e)

1H NMR (300 MHz, DMSO) δ 7.98 (s, 1H), 7.71 (s, 1H), 7.62-7.42 (m, 4H), 7.26-7.09 (m, 2H), 6.15 (s, 1H), 4.33 (s, 1H), 3.93 (s, 1H), 3.16-2.90 (m, 4H), 2.73 (t, J = 16.1 Hz, 3H), 2.55-2.37 (m, 4H), 2.36-2.30 (m, 3H).

2-(4-bromophenyl)-3-(2-hydroxy-3-(4-oxopiperidin-1-yl) propyl) quinazolin-4(3H)-one (5f)

1H NMR (300 MHz, DMSO) δ 7.98 (s, 1H), 7.70 (s, 1H), 7.54-7.41 (m, 6H), 6.15 (s, 1H), 3.93 (s, 1H), 3.78 (s, 1H), 3.28-3.21 (m, 2H), 3.07 (d, J = 11.2 Hz, 2H), 2.96 (s, 1H), 2.76-2.69 (m, 2H), 2.69-2.48 (m, 4H). m/z 455.02.

2-(4-fluorophenyl)-3-(2-hydroxy-3-(4-oxopiperidin-1-yl) propyl) quinazolin-4(3H)-one (5g)

1 H NMR (300 MHz, DMSO) δ 7.98 (s, 1H), 7.70 (s, 1H), 7.63-7.54 (m, 2H), 7.46 (d, J = 7.4 Hz, 2H), 7.13-6.98 (m, 2H), 6.16 (s, 1H), 3.95 (s, 1H), 3.80 (s, 1H), 3.28-3.20 (m, 2H), 3.16-2.88 (m, 3H), 2.79-2.66 (m, 2H), 2.61-2.45 (m, 4H). m/z 395.42

2-(3-bromophenyl)-3-(2-hydroxy-3-(4-oxopiperidin-1-yl) propyl) quinazolin-4(3H)-one (5h)

1 H NMR (300 MHz, DMSO) δ 7.98 (s, 1H), 7.84 (s, 1H), 7.70 (s, 1H), 7.59-7.40 (m, 4H), 7.21 (s, 1H), 6.16 (s, 1H), 3.95 (s, 1H), 3.77 (s, 1H), 3.31-3.18 (m, 2H), 3.16-2.88 (m, 3H), 2.76-2.66 (m, 2H), 2.61-2.44 (m, 4H).

Protocol for Evaluating Antimalarial Activity of Analogues Against Plasmodium berghei and Plasmodium yolli Strains

The method used for screening of the synthesized compounds for their blood schizonticidal activity [14] is based on a comparison of responses by groups of treated and control mice, six in each group, after infection with P. berghei (obtained from NIMR, New Delhi, India). Using standard inoculums of P. berghei (1Χ10 7 infected red cells), it is possible to produce a uniform disease that is fatal to 100% of untreated animals, within 6-8 days, with a mean survival time of 6.2 days. Test animals (Swiss mice of either sex, approximately 29΁2 g and same age) were housed in metal-topped cages, given a standard laboratory diet and water ad libitum. In order to check factors such as changes in the infectivity of the strain or in the susceptibility of the host or to detect technical errors, a group of infected animals treated with chloroquine diphosphate and sodium artesunate at dose levels 10 mg/kg/day for 4 days, producing definite increase in survival time, is included as a positive control in every experiment. In each experiment, the test compounds were administered in graded doses of 100, 50, 25, 10 and 5 mg/kg. The compounds showing positive biological activity at 50 mg/kg were further selected for screening at lower doses. On day 0, groups of six mice each were inoculated intraperitoneally with 1Χ10 6 infected erythrocytes in PBS solution from a donor mouse. Four hours later, mice were administered test compounds/ Chloroquine (CQ)/sodium artesunate/vehicle orally. A total of four doses were given orally on days D0, D1, D2, and D3. The thick and thin films blood smears (blood collected from tail vain) were made on D4 and D7, fixed with methanol and stained with 4% Giemsa at pH 7.2 for 45 min and examined microscopically [Figure 4] in agreement with study results of Peters. One group was left untreated as a positive control. Three different fields were examined on each slide and the number of infected and uninfected red blood cells (RBC) counted and the mean taken. The experimental design was similar to the 4-day suppressive test. [15]
Figure 4 :(a) Untreated; (b) treated with chloroquine; (c) treated with sodium artesunate; (d) treated with compound 5a

Click here to view

Percent parasitemia was calculated using the following formula:

where PRBC is parasitized red blood cells.

Average percentage of parasitemia suppression was calculated with the following formula: [16]

The minimum dose that completely suppressed parasitemia on D4 and D7 was termed as effective suppressive dose (ESD), and the minimum dose that cleared the parasitemia for up to the next 30 days was termed as therapeutically effective dose (TED).

Acute toxicity study was conducted for the active extracts (single dose 2000 mg/kg) using the method of Weil. [17] Albino mice weighing 20-25 g of either sex were divided into groups of five mice each. Each group received the test compounds orally. Signs of toxicity were observed for the first 2 hours and in 2 hours interval for 6 hours. Mortality was assessed after 24 hours.

   Results and Discussion Top

The results of acute toxicity studies in Swiss mice show that all the synthesized compounds were safe and non toxic up to 1000 mg/kg as compared to 88 mg/kg for febrifugine. All of the synthesized compounds were tested for in vivo blood schizonticidal activity against P. berghei infected mice model. The dose tested orally were 100, 50, 25, 10 and 5 mg/kg/day for 4 days. The results for all analogues were compared to a positive control group and negative control group (in this case, all animals usually died by D15) of mice treated with CQ and sodium artesunate (Sod.A rte ) at the concentration of 10 mg/kg/day Χ 4 days [Table 1], with mice showing negative parasitemia on D4 and D7.
Table 1 :In vivo antimalarial activity of synthesized compounds

Click here to view

The term "therapeutically effective" indicates complete elimination of malaria parasites from the body so that relapse will not occur up to day D30. The term "active" or ESD indicates that the treated animals show negative parasitemia up to D7. However, by D28 to D29, some mice showed negative and some mice showed positive test results for parasitemia. The term "inactive" indicates that the treated animals showed positive test result for parasitemia either on D4 or D7 or on both D4 and D7. All of the 2,3-substituted quinazolin-4(3H)-one derivatives (5a-f) were found to be more or equally active in the P. berghei test. The most effective compound 5a produced 100% cures at the preliminary tested dose of 50 mg/kg, but exhibited no curing result at 5 mg/kg.

   Conclusion Top

In summary, the antimalarial activity of 2,3-substituted quinazolin-4(3H)-one derivative has been identified. Substitution of 2 position of quinazolinone ring does not improve the activity markedly, thereby necessitating further exploration of the most suitable substitution at the N3 positions of quinazolinone. The biological evaluations of these are under process. The results of this study clearly establish that the potent antimalarial activity displayed by analogue 5a is attributed to the incorporation of quinazolinone group of febrifugine, and its 2-arryl substituted analogues do not alter the antimalarial activity.

   Acknowledgement Top

The authors acknowledge Mr. Subir Pal, CEO/President of Bengal Institute of Pharmaceutical Sciences, Kalyani and Jadavpur University, Kolkata, for providing financial and technical support for this work. One of the authors is also grateful to Dr. Pellai (NIMR, New Delhi, India), Dr. Ajit S. Singh (Scientist, DRDO, Kanpur, India) and Dr. Arup Mukherjee (Calcutta University, Kolkata, India) for their invaluable technical advice for finishing the project in time.

   References Top

1.Snow RW, Guerra CA, Noor AM, Myint HY, Hay SI. The global distribution of clinical episodes of Plasmodium falciparum malaria. Nature 2005;434:214-7.  Back to cited text no. 1
2.Bowman S, Lawson D, Basham D, Brown D, Chillingworth T, Churcher CM, et al. The complete nucleotide sequence of chromosome 3 of Plasmodium falciparum. Nature 1999;400:532-8.  Back to cited text no. 2
3.Gupta D, Yedidi RS, Varghese S, Kovari LC, Woster PM. Mechanism-based inhibitors of the aspartyl proteaase plasmepsin II as potential antimalarial agents. J Med Chem 2010;53:4234-47.  Back to cited text no. 3
4.Kikuchi H, Tasaka H, Hirai S, Takaya Y, Iwabuchi Y, Ooi H, et al. Potent antimalarial febrifugine analogues against the plasmodium malaria parasite. J Med Chem 2002;45:2563-70.   Back to cited text no. 4
5.Xie A, Sivaprakasam P, Doerksen RJ. 3D-QSAR analysis of antimalarial farnesyltransferase inhibitors based on a 2,5-diaminobenzophenone scaffold. Bioorg Med Chem 2006;14:7311-23.  Back to cited text no. 5
6.Koepfli JB, Mead JF, Brockman JA Jr. An alkaloid with high antimalarial activity from Dichroa febrifuga. J Am Chem Soc 1947;69:1837.  Back to cited text no. 6
7.De Smet PA. The role of plant-derived drugs and herbal medicines in healthcare. Drugs 1997;54:801-40.  Back to cited text no. 7
8.Kikuchi H, Yamamoto K, Horoiwa S, Hirai S, Kasahara R, Hariguchi N, et al. Exploration of a new type of antimalarial compounds based on febrifugine. J Med Chem 2006;49:4698-706.  Back to cited text no. 8
9.Kikuchi H, Yamamoto K, Horoiwa S, Hirai S, Kasahara R, Hariguchi N, et al. Exploration of a new type of antimalarial compounds based on febrifugine. J Med Chem 2006;49:4698-706.  Back to cited text no. 9
10.Cruickshank PA. Febrifugine Antimalarial Agent. I Pyridine Analogs of febrifugine. Central research Department, New Jersey; 1970.   Back to cited text no. 10
11.Zhu S, Meng L, Zhang Q, Wei L. Synthesis and evaluation of febrifugine analogues as potential antimalarial agents. Bioorg Med Chem Lett 2006;16:1854-8.  Back to cited text no. 11
12.Jiang S, Zeng Q, Gettayacamin M, Tungtaeng A, Wannaying S, Lim A, et al. Antimalarial activities and therapeutic properties of febrifugine analogs. Antimicrob Agents Chemother 2005;49:1169-76.  Back to cited text no. 12
13.Kang H, Wang GH. Benign and Efficient Synthesis of 2-Substituted 4 (3H) Quinazolinones Mediated by Iron (III) Chloride Hexahydrate in Refluxing Water. [Bull. Chem. Soc. Jpn.] 2006;79:1426-30.  Back to cited text no. 13
14.Knight DJ, Peters W. The antimalarial activity of N-benzyloxydihydrotriazines. I. The activity of clociguanil (BRL 50216) against rodent malaria, and studies on its mode of action. Ann Trop Med Parasitol 1980;74:393-404.  Back to cited text no. 14
15.Peters W, Robinson BL, Tovey G, Rossier JC, Jefford CW. The chemotherapy of rodent malaria. L. The activities of some synthetic 1,2,4-trioxanes against chloroquine-sensitive and chloroquine-resistant parasites. Part 3: Observations on 'Fenozan-50F', a difluorinated 3,3'-spirocyclopentane 1,2,4-trioxane. Ann Trop Med Parasitol 1993;87:111-23.  Back to cited text no. 15
16.Kimbi HK, Fagbenro-Beyioku AF, Oyibo WA. Antimalarial herbs against chloroquine-resistant P. yoelii nigeriensis in mice. Indian J Malariol 1998;35:35-8.  Back to cited text no. 16
17.Weil CS. Tables for convenient calculation of median effective dose and instructions in their use. Biometrics 1952;8:247.  Back to cited text no. 17


  [Figure 1], [Figure 2], [Figure 3], [Figure 4]

  [Table 1]

This article has been cited by
1 Investigation of catalytic performance of Bis [hydrazinium (1+)] hexafluoridosilicate: (N2H5)2SiF6 in synthesis of 2,4,5-triaryl-1H-imidazoles and 2,3-dihydroquinazolin-4 (1H)-ones under Green conditions
Fatima El hajri, Zakaria Benzekri, Haddou Anahmadi, Sarra Sibous, Ali Ouasri, Abdelaziz Souizi, Amina Hassikou, Ali Rhandour, Said Boukhris
Inorganica Chimica Acta. 2022; : 120915
[Pubmed] | [DOI]
2 Selective electrophilic di- and monofluorinations for the synthesis of 4-difluoromethyl and 4-fluoromethyl quinazolin(thi)ones by a Selectfluor-triggered multi-component reaction
Ruiqin Zhang, Renchao Ma, Qinjiao Fu, Rener Chen, Zhiming Wang, Lei Wang, Yongmin Ma
Organic Chemistry Frontiers. 2022;
[Pubmed] | [DOI]
3 Synthesis, antimalarial, antileishmanial evaluation, and molecular docking study of some 3-aryl-2-styryl substituted-4(3H)-quinazolinone derivatives
Girma Worku Seifu, Yihenew Simegniew Birhan, Botros Youssef Beshay, Ariaya Hymete, Adnan Ahmed Bekhit
BMC Chemistry. 2022; 16(1)
[Pubmed] | [DOI]
4 A Novel Powerful Choline Chloride - Thiourea/Sulfuric Acid: An Efficient and Recyclable Catalyst Used for the Microwave-assisted Synthesis of Quinazolin- 4(3H)-one Derivatives Used as Antibacterial Agents in Green Media
Fateme Haji Norouzi, Naser Foroughifar, Alireza Khajeh-Amiri, Hoda Pasdar
Current Microwave Chemistry. 2022; 9(1): 18
[Pubmed] | [DOI]
5 MSCs as Tumor-Specific Vectors for the Delivery of Anticancer Agents—A Potential Therapeutic Strategy in Cancer Diseases: Perspectives for Quinazoline Derivatives
Monika Szewc, Elzbieta Radzikowska-Buchner, Paulina Wdowiak, Joanna Kozak, Piotr Kuszta, Ewa Niezabitowska, Joanna Matysiak, Konrad Kubinski, Maciej Maslyk
International Journal of Molecular Sciences. 2022; 23(5): 2745
[Pubmed] | [DOI]
6 Anticancer Biological Profile of Some Heterocylic Moieties-Thiadiazole, Benzimidazole, Quinazoline, and Pyrimidine
Parin Salim Sidat, Tasneem Mohamadbin Kasim Jaber, Shwetang Ramesh Vekariya, Azmin Mahervan Mogal, Aarifa Mustak Patel, Malleshappa Noolvi
Pharmacophore. 2022; 13(4): 59
[Pubmed] | [DOI]
7 One-Pot, Borax-mediated synthesis of structurally diverse N, S-heterocycles in water
Mugada Sugunakara Rao,Sahid Hussain
Tetrahedron Letters. 2021; : 153159
[Pubmed] | [DOI]
8 Synthesis, Characterization, and Antifungal Activity of Some New Thieno[2,3-b]pyridines Incorporating Quinazoline or Benzimidazole Moiety
O. F. Ibrahim,E. A. Bakhite,S. A. M. Metwally,Y. A. El-Ossaily,H. H. M. Abdu-Allah,E. A. Al-Taifi,M. Kandel
Russian Journal of Bioorganic Chemistry. 2021; 47(4): 918
[Pubmed] | [DOI]
9 Synthesis of 2,3-dihydroquinazolin-4(1 H )-ones in the presence of Fe 3 O 4 @nano-cellulose–OPO 3 H as a bio-based magnetic nanocatalyst
Bi Bi Fatemeh Mirjalili,Zahra Zaghaghi,Aazam Monfared
Journal of the Chinese Chemical Society. 2019;
[Pubmed] | [DOI]
10 An Efficient, Convenient, and Solvent-Free Synthesis of 2,3-Dihydroquinazolin-4(1 H)-ones Using Montmorillonite-KSF Clay as a Heterogeneous Catalyst
Sunil U. Tekale,Shivaji B. Munde,Sushama S. Kauthale,Rajendra P. Pawar
Organic Preparations and Procedures International. 2018; 50(3): 314
[Pubmed] | [DOI]
11 Current perspectives on quinazolines with potent biological activities: A review
Tanya Gupta,Ankit Rohilla,Ankita Pathak,Md Jawaid Akhtar,Md Rafi Haider,M. Shahar Yar
Synthetic Communications. 2018; : 1
[Pubmed] | [DOI]
12 One-pot, four-component synthesis of spiroindoloquinazoline derivatives as phospholipase inhibitors
Maryam Beyrati,Maryam Forutan,Alireza Hasaninejad,Erik Rakovský,Somayyeh Babaei,Ammar Maryamabadi,Gholamhossein Mohebbi
Tetrahedron. 2017; 73(34): 5144
[Pubmed] | [DOI]
13 Halofuginone — The Multifaceted Molecule
Mark Pines,Itai Spector
Molecules. 2015; 20(1): 573
[Pubmed] | [DOI]
14 Synthesis, characterization and antimicrobial studies of new 2-(2-chloroquinolin-3-yl)-3-(substituted phenyl/pyridinyl)quinazolin-4(3H)-one derivatives using l-proline as a catalyst
Ritu Dixit,Hemal Mehta,Bharat Dixit
Medicinal Chemistry Research. 2014;
[Pubmed] | [DOI]
15 Synthesis and antimicrobial activity of some new 2,3-disubstituted quinazoline-4(3H)-ones derivatives
Abd-Elhakeem, M.A. and Elsayed, A.M.
Journal of Chemical and Pharmaceutical Research. 2013; 5(5): 275-279
Abha Shrivastava, A. B. Mundada, A. K. Pathak
PHARMACIA. 2011; 1(2)


    Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
    Access Statistics
    Email Alert *
    Add to My List *
* Registration required (free)  

  In this article
    Materials and Me...
    Results and Disc...
    Article Figures
    Article Tables

 Article Access Statistics
    PDF Downloaded621    
    Comments [Add]    
    Cited by others 16    

Recommend this journal